NeuroGeneration is a privately held biopharmaceutical company committed to accelerate clinical trials addressing important neurological disorders. NeuroGeneration pioneered the first human transplantation using autologous neural stem cells-derived neurons for advanced Parkinson's disease in 1998. Acquired in 2001 by Theratechnologies, a Canadian life science company, its subsidiary Celmed Biosciences furthered its development along other cell therapy programs. Reacquired in June of 2005, it is focused on completing Phase II study for advanced Parkinson's Disease and initiate pilot studies for several other neurological disorders.

NeuroGeneration's neural stem cell therapy for Parkinson's disease is now entering Phase II human clinical trial. It is planning to upgrade its current tissue culture rooms to meet good manufacturing products (GMP) requirements. Its corporate offices are located in Los Angeles, California.